PE9899A1 - Progesterona para tratar o reducir isquemia - Google Patents

Progesterona para tratar o reducir isquemia

Info

Publication number
PE9899A1
PE9899A1 PE1997000985A PE00098597A PE9899A1 PE 9899 A1 PE9899 A1 PE 9899A1 PE 1997000985 A PE1997000985 A PE 1997000985A PE 00098597 A PE00098597 A PE 00098597A PE 9899 A1 PE9899 A1 PE 9899A1
Authority
PE
Peru
Prior art keywords
progesterone
treat
refers
reduce ischemia
menopausic
Prior art date
Application number
PE1997000985A
Other languages
English (en)
Inventor
William J Bologna
Howard L Levine
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24987712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE9899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of PE9899A1 publication Critical patent/PE9899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE AL USO DE PROGESTERONA EN COMBINACION CON ESTROGENOS PARA LA PREPARACION DE UNA COMPOSICION PARA TRATAR O REDUCIR LA ISQUEMIA MIOCARDICA INDUCIDA POR ESFUERZO. TAMBIEN SE REFIERE A UNA FORMULACION PARA LA ADMINISTRACION VAGINAL QUE COMPRENDE: UN POLIMERO DE ACIDO POLICARBOXILICO QUE CONTIENE UN AGENTE ENTRECRUZADOR Y PROGESTERONA. LAS TERAPIAS DE REEMPLAZO HORMONAL DE ESTROGENO EN MUJERES MENOPAUSICAS SE ADMINISTRAN CONJUNTAMENTE CON PROGESTINAS PARA OPONER CUALQUIER TENDENCIA DE LOS ESTROGENOS A PROMOVER MALIGNIDAD UTERINA, SIN EMBARGO LA PROGESTERONA, A DIFERENCIA DE LAS PROGESTINAS SINTETICAS, MANTIENE O REDUCE LA ISQUEMIA EN LUGAR DE AUMENTARLA
PE1997000985A 1996-11-04 1997-11-04 Progesterona para tratar o reducir isquemia PE9899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/743,153 US5985861A (en) 1996-11-04 1996-11-04 Progesterone for treating or reducing ischemia

Publications (1)

Publication Number Publication Date
PE9899A1 true PE9899A1 (es) 1999-02-08

Family

ID=24987712

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000985A PE9899A1 (es) 1996-11-04 1997-11-04 Progesterona para tratar o reducir isquemia

Country Status (27)

Country Link
US (2) US5985861A (es)
EP (1) EP0956023B1 (es)
KR (1) KR100434623B1 (es)
CN (1) CN100341512C (es)
AR (1) AR009407A1 (es)
AT (1) ATE321558T1 (es)
AU (1) AU715740C (es)
BR (1) BR9710918A (es)
CA (1) CA2270565C (es)
DE (1) DE69735598T2 (es)
DK (1) DK0956023T3 (es)
ES (1) ES2262196T3 (es)
GE (1) GEP20022630B (es)
HK (1) HK1020534A1 (es)
HU (1) HUP9904045A3 (es)
IL (1) IL127455A (es)
LV (1) LV12342B (es)
MA (1) MA24391A1 (es)
MY (1) MY121627A (es)
NO (1) NO324278B1 (es)
NZ (1) NZ335306A (es)
PE (1) PE9899A1 (es)
PT (1) PT956023E (es)
RO (1) RO120607B1 (es)
UA (1) UA66772C2 (es)
WO (1) WO1998019681A1 (es)
ZA (1) ZA979862B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6602487B1 (en) 1997-02-26 2003-08-05 Dimera Incorporated Methods and tests for producing and for inhibiting coronary artery vasospasms
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
AU2004233997C1 (en) * 2003-04-29 2014-01-30 Massachusetts Institiute Of Technology Methods and devices for the sustained release of multiple drugs
DE102005027004B4 (de) * 2005-06-10 2020-03-19 Continental Automotive Gmbh Scheibenwaschvorrichtung
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
SI2359807T1 (sl) 2008-02-04 2017-10-30 Ferring B.V. Monolitni intravaginalni obroč, ki vsebuje progesteron ter postopki za njegovo izdelavo in uporabo
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
JP2021535183A (ja) 2018-09-07 2021-12-16 トラスティーズ・オヴ・ダートマス・カレッジ Ｃ１９骨格およびステロイドならびにそれらの使用および製造方法
US11512107B2 (en) 2018-09-07 2022-11-29 Trustees Of Dartmouth College Methods for assembly of tetracyclic compounds by stereoselective C9-C10 bond formation
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1124906A1 (ru) * 1982-05-25 1984-11-23 Ивановский государственный медицинский институт им.А.С.Бубнова Способ коррекции ишемических повреждений консервированной донорской почки
EP0501523B1 (en) * 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof

Also Published As

Publication number Publication date
ZA979862B (en) 1998-05-25
US6054447A (en) 2000-04-25
US5985861A (en) 1999-11-16
LV12342A (lv) 1999-09-20
AU715740C (en) 2004-04-29
AU5180198A (en) 1998-05-29
EP0956023B1 (en) 2006-03-29
KR20000053056A (ko) 2000-08-25
MA24391A1 (fr) 1998-07-01
CA2270565A1 (en) 1998-05-14
IL127455A (en) 2005-03-20
CN100341512C (zh) 2007-10-10
NO992140L (no) 1999-05-04
HUP9904045A3 (en) 2000-11-28
HUP9904045A2 (hu) 2000-04-28
NO992140D0 (no) 1999-05-03
ES2262196T3 (es) 2006-11-16
IL127455A0 (en) 1999-10-28
NZ335306A (en) 2000-12-22
DE69735598D1 (de) 2006-05-18
NO324278B1 (no) 2007-09-17
GEP20022630B (en) 2002-02-25
RO120607B1 (ro) 2006-05-30
LV12342B (en) 2000-01-20
ATE321558T1 (de) 2006-04-15
EP0956023A1 (en) 1999-11-17
BR9710918A (pt) 2000-01-11
DK0956023T3 (da) 2006-08-07
DE69735598T2 (de) 2006-12-28
AU715740B2 (en) 2000-02-10
MY121627A (en) 2006-02-28
KR100434623B1 (ko) 2004-06-05
WO1998019681A1 (en) 1998-05-14
HK1020534A1 (en) 2000-05-12
CN1235549A (zh) 1999-11-17
AR009407A1 (es) 2000-04-12
PT956023E (pt) 2006-08-31
UA66772C2 (uk) 2004-06-15
CA2270565C (en) 2007-02-20

Similar Documents

Publication Publication Date Title
PE9899A1 (es) Progesterona para tratar o reducir isquemia
PT748190E (pt) Metodos e formulacoes para uso no tratamento de disturbios ginecologicos benignos
EP1319404A3 (de) Mittel zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
Martin et al. Systemic absorption and sustained effects of vaginal estrogen creams
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
PE20051038A1 (es) Uso extendido de combinacion que comprende estrogenos y progestinas
PT836506E (pt) Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
FI900052A (fi) Kompositioner och behandlingsmetoder foer hemorrojder och annat.
MEP38008A (en) Drospirenone for hormone replacement therapy
AR031563A1 (es) Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u
BR9813262A (pt) Terapia de progestina com sangramento controlado
AR033042A1 (es) Terapia de reemplazo hormonal
AR017222A1 (es) Procedimiento de utilizacion de un agente que inhibe el desarrollo de p.ovale, en la preparacion de medicamentos
YU19399A (sh) Lokalni anestetik za spoljnu upotrebu
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
BR9712274A (pt) Composição hormonal consistindo de um composto de estrogênio e um composto progestacional
EA200100828A1 (ru) 16-гидроксиэстратриены в качестве эстрогенов избирательного действия
CO5590926A2 (es) Uso de anastrozol para el tratamiento de mujeres posmenopausicas que tienen cancer precoz de mama
PL312983A1 (en) Therapeutic preparation
PT927031E (pt) Composicao farmaceutica que contem nimesulide para administracao por via oral
CL2004000579A1 (es) Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria.
BR0010070A (pt) Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio
Goldman Spread of Condyloma Acuminata to Infants and Children-Reply
Whitcroft et al. HRT: Developments in therapy

Legal Events

Date Code Title Description
FC Refusal